PGC-1 α and Myokines in the Aging Muscle – A Mini-Review

Anne-Sophie Arnold Anna Egger Christoph Handschin

Biozentrum, Division of Pharmacology/Neurobiology, University of Basel, Basel, Switzerland

Key Words

Sarcopenia • Skeletal muscle • Peroxisome proliferator-activated receptor γ coactivator-1 α • Myokines • Transcriptional regulation

Abstract

Aging is associated with far-reaching changes in physiological functions resulting in morbidity and ultimately death. Age-related frailty, insecurity and reduced physical activity contribute to a progressive loss of muscle mass and function, commonly referred to as sarcopenia. Due to the increase in life expectancy in many countries, loss of muscle mass and its consequences gain in relevance for public health. At the same time, the molecular mechanisms that underlie sarcopenia are poorly understood and therefore, therapeutic approaches are limited. Interestingly though, endurance, strength and stretching exercise is significantly superior to all known pharmacological, nutritional and hormonal interventions for stabilizing, alleviating and reversing sarcopenia. Thus, increased knowledge about the plastic changes of skeletal muscle after physical activity and the signaling factors that mediate the beneficial effects of exercise on other organs might yield a better understanding of the disease and open new avenues for treatment. Here, we discuss how current discoveries about the peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1 α), a key

exercise factor in muscle, and myokines, factors produced and secreted by active muscle fibers, expand our view of the pathological changes and the therapeutic options for sarcopenia.

Copyright © 2010 S. Karger AG, Basel

Introduction

Improved public health, nutrition, education and medical care have culminated in a dramatic increase in life expectancy in many industrialized countries [1]. As a consequence, the drastically higher proportion of elderly individuals evokes new socioeconomic and public health problems.

Senescence is characterized by a progressive decline in physiological functions of all organs, ultimately resulting in morbidity and death [1]. Loss of independence and the necessity of care are caused by mental and physical decline. One important factor is the decrease in mobility due to the age-related reduction in muscle mass and function, collectively referred to as sarcopenia [2–5]. Socially, reduced mobility often results in a dimin-

A.-S. Arnold and A. Egger contributed equally.

Fig. 1. Potential causes and pathophysiological consequences of sarcopenia. Age-related changes in physiological properties and social behavior favor molecular adaptations that could contribute to the causation and progression of sarcopenia. The resulting frailty, immobility and weakness further feed the vicious cycle and ultimately increase morbidity and mortality.

ished ability of performing daily tasks and social interactions. Physically, loss of muscle mass greatly increases co-morbidities, mortality and thereby reduces life expectancy [6]. Regardless of gender, ethnicity and other factors, between 1 and 2% of muscle mass per year are lost in individuals from the fourth decade on [6, 7]. Furthermore, this rate accelerates after the age of 65 [6, 7]. While sarcopenia per se seems inevitable, the question about the possibilities for slowing or reversal of this process arises.

Causes and Treatment of Sarcopenia

Many different factors and pathways have been implicated in the etiology of sarcopenia (fig. 1). However, the relevance and relative importance of these potential causes are largely unknown. Furthermore, some of these observations are controversial, e.g. the preferential loss of glycolytic, fast-twitch type II muscle fibers in sarcopenia, and might depend on individual context, study population or even species [8]. The details about these postu-

lated mechanisms and a critical discussion of the relative relevance can be found in recent review articles [2–4, 6, 8–11].

Muscle mass and fiber size are primarily determined by the balance between protein biosynthesis and degradation. In addition, fiber repair and regeneration contribute to maintenance of muscle tissue. Both of these processes are impaired in the elderly. Satellite cells, the adult muscle stem cells that are recruited for fiber regeneration and hypertrophy, exhibit a reduced myogenic potential with aging [12]. This might be due to a decline in the number of muscle cell precursors and an augmented inability of these cells to respond to anabolic stimuli such as the insulin-like growth factor 1 (IGF-1) accompanied by a decrease in the expression of myogenic regulatory factors involved in muscle cell maturation [13, 14]. IGF-1 increases muscle mass and fiber hypertrophy by promoting anabolic processes, activation of satellite cells and their subsequent fusion with muscle fibers [15]. During senescence, decreased growth hormone levels and the resulting reduction in IGF-1 signaling contribute to the failure to sustain muscle mass. Thus, modulation of the

growth hormone/IGF-1 axis has been proposed as a therapeutic strategy to combat sarcopenia [16].

Muscle protein synthesis following food intake is reduced in sarcopenic muscle [17]. In fact, muscle tissue in the elderly seems less responsive to the anabolic effect of amino acids [17]. Accordingly, nutritional interventions aiming at activating the mammalian target of rapamycin (mTOR) pathway and thereby increasing protein biosynthesis in muscle have limited effects in sarcopenia [17, 18]. To make matters worse, dietary interventions with increased protein or caloric load can be counterproductive by exacerbating the gain of fat mass that is observed in many elderly individuals [6, 17]. In contrast, and seemingly paradoxical, calorically restricted diets are potentially more efficacious against sarcopenia by promoting mitochondrial function and modulating apoptotic and autophagic pathways [2, 19]. Caloric restriction and direct pharmacological interventions of the putative downstream mediators mTOR and sirtuin 1 (SIRT1) increase lifespan in a number of different organisms, including mammals [20, 21]. However, some of the pharmacological interventions have limited effects on 'healthspan', i.e. the number of healthy years, or produce unwanted side effects as observed in mice treated with rapamycin, an mTOR inhibitor, which despite an increased lifespan had a higher incidence of cancer and cardiovascular disease [20]. Furthermore, caloric restriction could be hazardous for certain populations by promoting anemia, neurological deficits, edema, weakness, dizziness, lethargy and irritability [22].

Exercise as a Therapeutic Option for Sarcopenia

The best therapeutic option against sarcopenia currently is exercise, which promotes gain of muscle mass and function [9, 17, 23]. Moreover, physical activity improves neuromuscular adaptation, reduces inflammation and enhances fiber strength and endurance, all of which are beneficial for sarcopenia patients. Accordingly, resistance-type and endurance exercises effectively improve muscle functionality in the elderly [17]. These training paradigms trigger specific adaptations in muscle fibers: resistance exercise promotes protein biosynthesis and hypertrophy of type IIx/b, glycolytic, fast-twitch fibers. In contrast, endurance training increases mitochondrial function and oxidative metabolism by selective activation of type I and type IIa, oxidative, slow-twitch, high endurance fibers [24]. However, in all fibers, disuse results in a shift towards protein degradation and fiber atrophy.

PGC-1 α : A Key Regulator of Trained Muscle

Our knowledge of the molecular mechanisms that regulate training adaptation in muscle is rudimentary. Calcium signaling seems important for resistance and endurance training while additional signaling pathways such as those induced by growth factors are involved in the specification of the adaptive response [25]. Interestingly though, in the endurance trained muscle, most signaling pathways that are activated subsequent to motor neuron activity, mechanical stress and altered nutrient and energy state converge on the peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1 α) by either inducing PPARGC1A gene expression or posttranslationally modifying the PGC-1 α protein [26–31]. PGC-1 α is a transcriptional coactivator that binds to a number of transcription factors and thereby potently induces gene expression [26–30]. PGC-1 α is detected in all oxidative tissues and is a strong promoter of mitochondrial biogenesis and function [26–30]. In addition, PGC-1 α regulates gene expression in a tissue-specific way. For example, PGC-1 α is essential for fasting-induced hepatic gluconeogenesis, cold-induced thermogenesis in brown adipose tissue and increased output of the working heart [32–34]. In all of these tissues, PGC-1 α activity is strongly regulated on the transcriptional and posttranslational level. Once activated in skeletal muscle, PGC-1 α in turn controls many if not all of the adaptations of muscle fibers to endurance training [35–37]. Accordingly, mice with ectopically expressed PGC-1 α in skeletal muscle exhibit fatigue-resistant muscle fibers and an improved endurance capacity [37, 38]. In contrast, animals lacking a functional PPARGC1A gene in skeletal muscle experience an impaired ability to exercise and show a number of signs that define a pathologically inactive muscle [35, 36].

Myokines as Mediators of Proximal and Distal Effects of Exercise

Repeated bouts of exercise affect almost every organ in our body and a sedentary lifestyle is an independent and strong risk factor for many chronic diseases [27, 39]. However, it is unclear how physiological processes in distal organs are modulated by trained muscle. About 10 years ago, a better understanding of this organ crosstalk was obtained by the discovery of hormonal factors that are produced and secreted by active muscle fibers [40–42]. Analogous to the adipokines, cytokines and other factors secreted from adipose tissue, muscle-derived pro-

Fig. 2. Myokine production and putative effects on muscle and distal organs. Myokines are produced and secreted by skeletal muscle and exert subsequent auto-, para- and endocrine effects. Physical activity (through PGC-1 α ?) and an inactive lifestyle as observed in sarcopenia control the production of myokines. FA = Fatty acid.

teins are called myokines [41, 42]. The first muscle-derived secreted protein to be described was the cytokine interleukin-6 (IL-6). Today, it is clear that many additional signaling molecules are produced by contracting muscle fibers and the current list of myokines includes IL-6, IL-8, IL-15, brain-derived neurotrophic factor (BDNF), leukemia inhibitory factor (LIF), follistatin-like 1 and fibroblast growth factor-21 (FGF21) [41–43].

The plasma levels of other cytokines, including tumor necrosis factor- α (TNF α), macrophage inflammatory protein-1 α and -1 β (MIP-1 α and MIP-1 β), IL-1 receptor antagonist (IL-1ra) and IL-10, are also elevated after exercise. However, it is unclear if these factors are produced by muscle or originate from immune cells or if these cytokines are the result of an inflammatory reaction since some of these cytokines are only observed after extremely strenuous exercise [44, 45]. Therefore, none of these factors are currently classified as bona fide myokines. Similarly, an augmentation of IL-4 and IL-13 was observed in human volunteers following strength training [46]. Further studies are needed to understand the role of these cytokines in the active muscle and to determine whether IL-4 and IL-13 are myokines.

Myokines act in an auto-, para- or endocrine fashion and thereby have major implications on metabolic and other properties of muscle as well as distal organs (fig. 2). For example, IL-6 induces glucose uptake and fatty acid β -oxidation in muscle, stimulates hepatic gluconeogenesis and induces lipolysis in fat [41]. Similarly, IL-15 seems to be involved in muscle-adipose tissue crosstalk [41]. High local IL-8 concentrations might be involved in exercise-induced angiogenesis and hence increased capillarization of skeletal muscle [41]. BDNF augments fatty acid β oxidation in muscle and might contribute to the muscle-brain crosstalk in exercise [41, 47].

PGC-1 α and Myokines in Sarcopenia

PGC-1 α expression levels are higher in type I and type IIa oxidative fibers compared to glycolytic fibers and in active versus inactive muscle [37, 48]. Accordingly, similar to other contexts of inadequate muscle activity, reduced PGC-1 α gene expression is observed in skeletal muscle of aged rats [49] and in the elderly compared to young individuals, at least in some human populations [50]. This reduction correlates with the impaired

oxidative capacity in sarcopenia [7, 9]. Furthermore, loss-of-function studies of PGC-1 α gene expression in murine skeletal muscle revealed a systemic, low-grade, chronic inflammation characterized by elevated circulating levels of IL-6 and TNF α [35, 36, 51]. The levels of these two cytokines are likewise pathologically elevated in sarcopenia and are strongly associated with increased mortality in these individuals [52]. In contrast, the production of IL-6 and some of the other myokines is very transient during exercise followed by a rapid normalization to pre-exercised levels shortly after a training bout [41]. Thus, the reduction of PGC-1 α transcription in an inactive muscle such as that in sarcopenia and the ensuing dysregulation of myokine production potentially contributes to the morbidity and mortality in this disease [27].

Therapeutic Potential

At the moment, it is unclear if the reduction of PGC-1 α in sarcopenic muscle is a general phenomenon (e.g. see [50, 53] for studies with diametrically opposed conclusions about the association between PGC-1 α expression and age in human muscle) and whether the dysregulation is cause or consequence of the muscle-wasting process in the elderly. In any case, recent advances imply that a modulation of PGC-1 α levels in muscle might be beneficial for sarcopenia patients. First, old rats with a blunted induction of PGC-1 α expression subsequent to exercise are also resistant to exercise-mediated improvement of sarcopenia [54]. Similarly, PGC-1 α is required for exercise-mediated prevention of the functional decline of mitochondrial enzymes in aging in mice [60]. Second, ectopic expression of PGC-1 α in skeletal muscle reduced muscle fiber damage, deterioration in innervation, and inflammation in old mice [55]. In addition, endurance capacity and survival of old muscle-specific PGC-1 α transgenic mice is increased compared to that of wild-type littermates [55]. Furthermore, similar gain-of-function studies in mouse models with muscle-specific, transgenically expressed PGC-1 α revealed an improvement of fiber integrity and muscle function in a variety of different muscle wasting contexts, including denervation-induced fiber atrophy, Duchenne muscular dystrophy, a mitochondrial myopathy and statin-mediated fiber damage [56–59]. The mechanisms by which PGC-1 α improves these muscle diseases with completely different etiology are unknown. However, several of the postulated pathological mechanisms in sarcopenia could

be rectified by PGC-1 α function, such as decreased mitochondrial function, impaired reactive oxygen species (ROS) detoxification, neuromuscular junction abnormalities or increased pro-inflammatory gene expression [27, 30]. In general, like patients suffering from other muscle-wasting diseases, elderly with sarcopenia would benefit from the ability of elevated PGC-1 α to induce a trained muscle phenotype regardless of the actual level of physical activity [30, 37, 38, 56].

Conclusion and Perspectives

Pharmacological interventions aimed at increasing PGC-1 α expression in muscle and at normalizing myokine production and secretion pattern would be promising new avenues for slowing down and reversing sarcopenia. Unfortunately, despite screening efforts, safe and chronically applicable compounds that robustly and selectively augment PGC-1 α activity in muscle remain elusive [30, 51]. Furthermore, drug-induced PGC-1 α expression will have to be achieved within a physiological, therapeutically beneficial window since in excess, PGC-1 α causes detrimental effects in muscle, heart and other tissues [30]. Similar to PGC-1 α , it is unclear how aberrant myokine levels can be normalized pharmacologically. Thus, more research on the upstream signaling and downstream effects of PGC-1 α and myokines in muscle as well as distal tissues is needed. Until then, a healthy and active lifestyle as prevention and exercise combined with nutritional and hormonal interventions as therapy remain the most promising weapons in the battle against sarcopenia and other ailments of old age.

Acknowledgments

We thank our colleagues for discussions, ideas and suggestions during the writing of this manuscript. Work in the authors' laboratory related to this review is supported by the Swiss National Science Foundation (SNF PP00A-110746), the Muscular Dystrophy Association USA (MDA), the SwissLife 'Jubiläumsstiftung für Volksgesundheit und medizinische Forschung', the Swiss Society for Research on Muscle Diseases (SSEM), the Swiss Diabetes Association, the Roche Research Foundation, the United Mitochondrial Disease Foundation (UMDF), the Association Française contre les Myopathies (AFM), and the University of Basel.

References

- Kirkwood TB: A systematic look at an old problem. *Nature* 2008;451:644–647.
- Marzetti E, Anne Lees H, Eva Wohlgemuth S, Leeuwenburgh C: Sarcopenia of aging: Underlying cellular mechanisms and protection by calorie restriction. *BioFactors* (Oxford) 2009;35:28–35.
- Marcell TJ: Sarcopenia: causes, consequences, and preventions. *J Gerontol A Biol Sci Med Sci* 2003;58:M911–M916.
- Doherty TJ: Invited review: aging and sarcopenia. *J Appl Physiol* 2003;95:1717–1727.
- Roubenoff R: Sarcopenia: effects on body composition and function. *J Gerontol A Biol Sci Med Sci* 2003;58:1012–1017.
- Saini A, Faulkner S, Al-Shanti N, Stewart C: Powerful signals for weak muscles. *Age Res Rev* 2009;8:251–267.
- Greenlund LJ, Nair KS: Sarcopenia – consequences, mechanisms, and potential therapies. *Mech Age Dev* 2003;124:287–299.
- Hepple RT: Sarcopenia – a critical perspective. *Sci Aging Knowledge Environ* 2003;2003:pe31.
- Johnston AP, De Lisio M, Parise G: Resistance training, sarcopenia, and the mitochondrial theory of aging. *Appl Physiol Nutr Metab* 2008;33:191–199.
- Marzetti E, Leeuwenburgh C: Skeletal muscle apoptosis, sarcopenia and frailty at old age. *Exp Gerontol* 2006;41:1234–1238.
- Ryall JG, Schertzer JD, Lynch GS: Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. *Biogerontology* 2008;9:213–228.
- Snijders T, Verdijk LB, van Loon LJ: The impact of sarcopenia and exercise training on skeletal muscle satellite cells. *Age Res Rev* 2009;8:328–338.
- Conboy IM, Conboy MJ, Smythe GM, Rando TA: Notch-mediated restoration of regenerative potential to aged muscle. *Science* 2003;302:1575–1577.
- Conboy IM, Rando TA: The regulation of notch signaling controls satellite cell activation and cell fate determination in postnatal myogenesis. *Dev Cell* 2002;3:397–409.
- Sandri M: Signaling in muscle atrophy and hypertrophy. *Physiology* (Bethesda) 2008;23:160–170.
- Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C: Modulation of GH/IgF-1 axis: potential strategies to counteract sarcopenia in older adults. *Mech Age Dev* 2008;129:593–601.
- Koopman R, van Loon LJ: Aging, exercise, and muscle protein metabolism. *J Appl Physiol* 2009;106:2040–2048.
- Paddon-Jones D, Short KR, Campbell WW, Volpi E, Wolfe RR: Role of dietary protein in the sarcopenia of aging. *Am J Clin Nutr* 2008;87:1562S–1566S.
- Mehta LH, Roth GS: Caloric restriction and longevity. *Ann NY Acad Sci* 2009;1172:28–33.
- Cox LS: Live fast, die young: new lessons in mammalian longevity. *Rejuvenation Res* 2009;12:283–288.
- Chen D, Guarente L: Sir2: a potential target for calorie restriction mimetics. *Trends Mol Med* 2007;13:64–71.
- Fontana L, Klein S: Aging, adiposity, and calorie restriction. *JAMA* 2007;297:986–994.
- Roubenoff R: Physical activity, inflammation, and muscle loss. *Nutr Rev* 2007;65:S208–S212.
- Fluck M: Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli. *J Exp Biol* 2006;209:2239–2248.
- Michel RN, Dunn SE, Chin ER: Calcineurin and skeletal muscle growth. *Proc Nutr Soc* 2004;63:341–349.
- Handschin C, Spiegelman BM: Pgc-1 coactivators, energy homeostasis, and metabolism. *Endocr Rev* 2006;27:728–735.
- Handschin C, Spiegelman BM: The role of exercise and PGC1alpha in inflammation and chronic disease. *Nature* 2008;454:463–469.
- Lin J, Handschin C, Spiegelman BM: Metabolic control through the PGC-1 family of transcription coactivators. *Cell Metab* 2005;1:361–370.
- Finck BN, Kelly DP: Pgc-1 coactivators: inducible regulators of energy metabolism in health and disease. *J Clin Invest* 2006;116:615–622.
- Handschin C: The biology of PGC-1alpha and its therapeutic potential. *Trends Pharmacol Sci* 2009;30:322–329.
- Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM: An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. *Proc Natl Acad Sci USA* 2003;100:7111–7116.
- Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jager S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Kraic D, Spiegelman BM: Defects in adaptive energy metabolism with cns-linked hyperactivity in PGC-1alpha null mice. *Cell* 2004;119:121–135.
- Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP: Pgc-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. *PLoS Biol* 2005;3:e101.
- Handschin C, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM: Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. *Cell* 2005;122:505–515.
- Handschin C, Chin S, Li P, Liu F, Maratos-Flier E, Lebrasseur NK, Yan Z, Spiegelman BM: Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. *J Biol Chem* 2007;282:30014–30021.
- Handschin C, Choi CS, Chin S, Kim S, Kawamori D, Kurpad AJ, Neubauer N, Hu J, Mootha VK, Kim YB, Kulkarni RN, Shulman GI, Spiegelman BM: Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. *J Clin Invest* 2007;117:3463–3474.
- Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. *Nature* 2002;418:797–801.
- Calvo JA, Daniels TG, Wang X, Paul A, Lin J, Spiegelman BM, Stevenson SC, Rangwala SM: Muscle-specific expression of PPAR{gamma} coactivator-1{alpha} improves exercise performance and increases peak oxygen uptake. *J Appl Physiol* 2008;104:1304–1312.
- Booth FW, Chakravarthy MV, Gordon SE, Spangenberg EE: Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. *J Appl Physiol* 2002;93:3–30.
- Febbraio MA, Pedersen BK: Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? *Exerc Sport Sci Rev* 2005;33:114–119.
- Pedersen BK: Edward f. Adolph distinguished lecture: muscle as an endocrine organ – IL-6 and other myokines. *J Appl Physiol* 2009;107:1006–1014.
- Pedersen BK: The diseasome of physical inactivity and the role of myokines in muscle-fat cross talk. *J Physiol* 2009;107:1006–1014.
- Walsh K: Adipokines, myokines and cardiovascular disease. *Circ J* 2009;73:13–18.
- Febbraio MA: Exercise and inflammation. *J Appl Physiol* 2007;103:376–377.
- Gleeson M: Immune function in sport and exercise. *J Appl Physiol* 2007;103:693–699.
- Prokopcuk O, Liu Y, Wang L, Wirth K, Schmidtbleicher D, Steinacker JM: Skeletal muscle IL-4, IL-4alpha, IL-13 and IL-13alpha1 expression and response to strength training. *Exerc Immunol Rev* 2007;13:67–75.
- Cotman CW, Berchtold NC, Christie LA: Exercise builds brain health: key roles of growth factor cascades and inflammation. *Trends Neurosci* 2007;30:464–472.

- 48 Pilegaard H, Saltin B, Neufer PD: Exercise induces transient transcriptional activation of the PGC-1 α gene in human skeletal muscle. *J Physiol* 2003;546:851–858.
- 49 Baker DJ, Betik AC, Krause DJ, Hepple RT: No decline in skeletal muscle oxidative capacity with aging in long-term calorically restricted rats: effects are independent of mitochondrial DNA integrity. *J Gerontol A Biol Sci Med Sci* 2006;61:675–684.
- 50 Ling C, Poulsen P, Carlsson E, Ridderstrale M, Almgren P, Wojtaszewski J, Beck-Nielsen H, Groop L, Vaag A: Multiple environmental and genetic factors influence skeletal muscle PGC-1 α and PGC-1 β gene expression in twins. *J Clin Invest* 2004;114:1518–1526.
- 51 Handschin C: Peroxisome proliferator-activated receptor- γ coactivator-1 α in muscle links metabolism to inflammation. *Clin Exp Pharmacol Physiol* 2009;36:139–143.
- 52 Roubenoff R, Parise H, Payette HA, Abad LW, D'Agostino R, Jacques PF, Wilson PW, Dinarello CA, Harris TB: Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. *Am J Med* 2003;115:429–435.
- 53 Short KR, Vittone JL, Bigelow ML, Proctor DN, Rizza RA, Coenen-Schimke JM, Nair KS: Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. *Diabetes* 2003;52:1888–1896.
- 54 Betik AC, Thomas MM, Wright KJ, Riel CD, Hepple RT: Exercise training from late middle age until senescence does not attenuate the declines in skeletal muscle aerobic function. *Am J Physiol Regul Integr Comp Physiol* 2009;297:R744–R755.
- 55 Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT: Increased muscle PGC-1 α expression protects from sarcopenia and metabolic disease during aging. *Proc Natl Acad Sci USA* 2009;106:20405–20410.
- 56 Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, Spiegelman BM: Pgc-1 α protects skeletal muscle from atrophy by suppressing foxo3 action and atrophy-specific gene transcription. *Proc Natl Acad Sci USA* 2006;103:16260–16265.
- 57 Handschin C, Kobayashi YM, Chin S, Seale P, Campbell KP, Spiegelman BM: Pgc-1 α regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy. *Genes Dev* 2007;21:770–783.
- 58 Wenz T, Diaz F, Spiegelman BM, Moraes CT: Activation of the ppar/PGC-1 α pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. *Cell Metab* 2008;8:249–256.
- 59 Hanai JI, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH: The muscle-specific ubiquitin ligase atrogin-1/mafbx mediates statin-induced muscle toxicity. *J Clin Invest* 2007;117:3940–3951.
- 60 Lotte L, Lyngy SS, Wojtaszewski JF, Pilegaard H: PGC-1 α is required for training-induced prevention of age-associated decline in mitochondrial enzymes in mouse skeletal muscle. *Exp Gerontol* 2010 [epub ahead of print].